View of Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China | Health Decision
Return to Article Details Cost effectiveness analysis of blonanserin versus ziprasidone as first-line treatment for patients with schizophrenia in China